Bone Biologics Corp financial data

Symbol
BBLG, BBLGW on Nasdaq
Location
2 Burlington Woods Drive,, Suite 100,, Burlington, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AFH ACQUISITION X, INC. (to 9/15/2014)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 18.6 % -62.4%
Return On Equity -154 % -24.9%
Return On Assets -130 % -57.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.8M shares -42.5%
Common Stock, Shares, Outstanding 1.32M shares -58%
Entity Public Float 4.16M USD -5.47%
Common Stock, Value, Issued 1.32K USD -58.1%
Weighted Average Number of Shares Outstanding, Basic 1.17M shares +244%
Weighted Average Number of Shares Outstanding, Diluted 1.17M shares +244%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.62M USD -59.2%
General and Administrative Expense 2.34M USD +2.35%
Operating Income (Loss) -4.95M USD +43%
Nonoperating Income (Expense) 25.9K USD -98%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.52M USD -33.6%
Income Tax Expense (Benefit) 33.1K USD
Net Income (Loss) Attributable to Parent -5.12M USD +11.8%
Earnings Per Share, Basic 25.8 USD/shares
Earnings Per Share, Diluted 25.8 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.19M USD +6.43%
Assets, Current 3.19M USD
Assets 3.19M USD -58.1%
Liabilities, Current 285K USD -85.3%
Liabilities 285K USD -85.3%
Retained Earnings (Accumulated Deficit) -82.6M USD -6.61%
Stockholders' Equity Attributable to Parent 2.91M USD -48.9%
Liabilities and Equity 3.19M USD -58.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.3M USD +3.45%
Net Cash Provided by (Used in) Financing Activities 1.5M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.32M shares -58%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 201K USD
Deferred Tax Assets, Valuation Allowance 20.4M USD +0.29%
Deferred Tax Assets, Gross 20.4M USD +0.29%
Deferred Tax Assets, Operating Loss Carryforwards 9.59M USD -12.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 85.5M USD +2.81%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%